SRPT INVESTOR REMINDER: Sarepta Therapeutics, Inc. Stock Drop Leads to Class Action – Investors with Losses Urged to Contact BFA Law by August 25 (NASDAQ:SRPT)

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317 [2]. - Investors have until August 25, 2025, to request to be appointed to lead the case [2]. Group 2: Product and Allegations - Sarepta is focused on developing treatments for rare diseases, with Elevidys being its key product for Duchenne muscular dystrophy [3]. - Allegations state that Sarepta misrepresented the safety profile of Elevidys, claiming its benefits outweighed risks, while it is linked to fatal acute liver failure in some patients [3]. Group 3: Stock Performance and Impact - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second patient death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third patient death related to Elevidys was reported on July 17, 2025, causing the stock to fall more than 40% on July 18, 2025 [5].